586858102

Yarrow Bioscience Inc.

Could not find a ticker for this position, may be a filing error

A clinical-stage biotech developing YB-101, a potential first-in-class antibody therapy for Graves' disease and thyroid eye disease, two autoimmune conditions that attack the thyroid. Founded and incubated by investment firm RTW Investments, it merged with VYNE Therapeutics in 2026 and kept the Yarrow name. That name nods to the yarrow flower, a legendary healing herb said to have been used by Greek hero Achilles to treat soldiers' wounds.